HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
BACKGROUND:The clinical significance and cellular sources of residual human immunodeficiency virus type 1 (HIV-1) production despite suppressive combination antiretroviral therapy (cART) remain unclear and the effect of low-level viremia on T-cell homeostasis is still debated. METHODOLOGY/PRINCIPAL...
Main Authors: | Maud Mavigner, Pierre Delobel, Michelle Cazabat, Martine Dubois, Fatima-Ezzahra L'faqihi-Olive, Stéphanie Raymond, Christophe Pasquier, Bruno Marchou, Patrice Massip, Jacques Izopet |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-10-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2765414?pdf=render |
Similar Items
-
Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens
by: Jean Michel Mansuy, et al.
Published: (2017-05-01) -
Genotypic prediction of HIV-1 subtype D tropism
by: Chaix Marie-Laure, et al.
Published: (2011-07-01) -
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.
by: Pierre Delobel, et al.
Published: (2011-01-01) -
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01) -
Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
by: Jana L. Jacobs, et al.
Published: (2019-10-01)